+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Berinert"

From
From
Plasma Protease C1-Inhibitor Global Market Report 2025 - Product Thumbnail Image

Plasma Protease C1-Inhibitor Global Market Report 2025

  • Report
  • July 2025
  • 175 Pages
  • Global
From
From
From
Hereditary Angioedema Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Hereditary Angioedema Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Hereditary Angioedema Market Report and Forecast 2025-2034 - Product Thumbnail Image

Hereditary Angioedema Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Berinert is a brand of Immune Disorders Drugs used to treat hereditary angioedema (HAE). It is a rare, genetic disorder that causes episodes of swelling in the face, extremities, gastrointestinal tract, and airway. Berinert is a C1-esterase inhibitor, which works by blocking the action of the enzyme that causes the swelling. It is administered as an intravenous infusion and is used to treat acute attacks of HAE. It is also used to prevent attacks in patients with a history of frequent attacks. Berinert is approved for use in adults and children over the age of two. The Berinert market is composed of a variety of companies that produce and distribute the drug. These include CSL Behring, Shire, and ViroPharma. Other companies involved in the market include Grifols, Kedrion, and Octapharma. These companies are involved in the production, distribution, and marketing of Berinert. They also provide support services to patients and healthcare professionals. Show Less Read more